The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Marcus Davidsson

Marcus Davidsson

Postdoctoral fellow

Marcus Davidsson

Next-Generation Gene Therapy for Parkinson's Disease Using Engineered Viral Vectors

Author

  • Tomas Björklund
  • Marcus Davidsson

Summary, in English

Recent technological and conceptual advances have resulted in a plethora of exciting novel engineered adeno associated viral (AAV) vector variants. They all have unique characteristics and abilities. This review summarizes the development and their potential in treating Parkinson's disease (PD). Clinical trials in PD have shown over the last decade that AAV is a safe and suitable vector for gene therapy but that it also is a vehicle that can benefit significantly from improvement in specificity and potency. This review provides a concise collection of the state-of-the-art for synthetic capsids and their utility in PD. We also summarize what therapeutical strategies may become feasible with novel engineered vectors, including genome editing and neuronal rejuvenation.

Department/s

  • Molecular Neuromodulation
  • MultiPark: Multidisciplinary research focused on Parkinson´s disease

Publishing year

2021

Language

English

Pages

209-217

Publication/Series

Journal of Parkinson's Disease

Volume

11

Issue

s2

Document type

Journal article review

Publisher

IOS Press

Topic

  • Neurosciences

Keywords

  • clinical trial
  • dependovirus
  • gene editing
  • Genetic therapy
  • neuroprotection
  • Parkinson's disease
  • rejuvenation

Status

Published

Research group

  • Molecular Neuromodulation

ISBN/ISSN/Other

  • ISSN: 1877-7171